News

Zacks Investment Research on MSN3h
Can Recent Pipeline Expansion Efforts Offset RXRX's Earlier Losses?
Recursion Pharmaceuticals RXRX faced a significant setback in May 2025 after announcing the discontinuation of three key drug candidates — REC-994, REC-2282, and REC-3964 — as part of its broader ...
Mixture-of-recursions delivers 2x faster inference—Here’s how to implement it
Mixture-of-Recursions (MoR) is a new AI architecture that promises to cut LLM inference costs and memory use without ...
Top 2 Health Care Stocks You May Want To Dump This Quarter
As of July 22, 2025, two stocks in the health care sector could be flashing a real warning to investors who value momentum as ...
Regulatory Green Lights Are Powering the Next Phase of the AI Health Boom
Detailed price information for Avant Technologies Inc (AVAI) from The Globe and Mail including charting and trades.
Recursion Pharmaceuticals Acquires Full Rights to REV102, Potential Oral Therapy for Rare Bone Disorder Hypophosphatasia
Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the best small cap AI stocks to buy according to analysts. On July 8, ...
Recursion Pharmaceuticals Rises 6% in a Month: How to Play the Stock
RXRX gains 5.5% in a month on positive pipeline update; long-term hold advised given strong potential of its AI-driven drug discovery platform.